Quick Answer
Jasper Therapeutics, Inc. reported Net Income of -$75.80 million for fiscal year 2025.
Jasper Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$75.80M -6.4% |
-$71.27M -10.6% |
-$64.47M -71.1% |
-$37.69M -23.0% |
-$30.64M +3.3% |
-$31.67M |
| Diluted EPS | -$3.95 +19.2% |
-$4.89 +20.9% |
-$6.18 +40.2% |
-$10.33 -284.0% |
-$2.69 | — |
| Total Assets | $35.78M -55.2% |
$79.90M -15.8% |
$94.89M +96.2% |
$48.36M -48.4% |
$93.65M +301.0% |
$23.36M -77.0% |
| Cash and Equivalents | $28.69M -59.9% |
$71.64M -17.6% |
$86.89M +127.2% |
$38.25M -54.8% |
$84.70M +327.0% |
$19.84M +1535.8% |
| Stockholders Equity | $4.15M -93.3% |
$61.67M -21.4% |
$78.44M +118.0% |
$35.99M -48.2% |
$69.52M +297.9% |
-$35.13M -642.1% |
| R&D Expense | $63.10M +13.0% |
$55.82M +7.8% |
$51.78M +49.6% |
$34.63M +36.2% |
$25.42M +60.1% |
$15.88M |
| Operating Income | -$83.88M -10.0% |
-$76.24M -10.7% |
-$68.86M -34.5% |
-$51.20M -1865.4% |
$2.90M +114.0% |
-$20.68M -813.2% |
| Shares Outstanding | 28.00M +86.4% |
15.02M +34.6% |
11.16M +193.4% |
3.80M -90.0% |
37.86M +1266.3% |
2.77M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$18.74M | -0.5% | +29.9% |
| Diluted EPS | September 30, 2025 | -$1.13 | +8.9% | +35.1% |
| Total Assets | September 30, 2025 | $57.47M | -42.2% | +23.7% |
| Cash and Equivalents | September 30, 2025 | $50.90M | -45.0% | +28.8% |
| Stockholders Equity | September 30, 2025 | $11.57M | -86.2% | -50.8% |
| R&D Expense | September 30, 2025 | $14.39M | -0.4% | -32.1% |
| Operating Income | September 30, 2025 | -$19.17M | +3.6% | +29.2% |
| Shares Outstanding | September 30, 2025 | 27.98M | +86.5% | +72.5% |
- Jasper Therapeutics, Inc. reported Net Income of -$75.80 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed a decrease of -6.4% in Net Income compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
- Jasper Therapeutics, Inc. showed an increase of +19.2% in Diluted EPS compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Total Assets of $35.78 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed a decrease of -55.2% in Total Assets compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Cash and Equivalents of $28.69 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed a decrease of -59.9% in Cash and Equivalents compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Stockholders Equity of $4.15 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed a decrease of -93.3% in Stockholders Equity compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported R&D Expense of $63.10 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed an increase of +13.0% in R&D Expense compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Operating Income of -$83.88 million for fiscal year 2025.
- Jasper Therapeutics, Inc. showed a decrease of -10.0% in Operating Income compared to the prior fiscal year.
- Jasper Therapeutics, Inc. reported Shares Outstanding of 28.00 million shares for fiscal year 2025.
- Jasper Therapeutics, Inc. showed an increase of +86.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: